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Background: Bladder cancer is one of the most common cancers worldwide. Fibulin-1, a multi-functional extracellular
matrix protein, has been demonstrated to be involved in many kinds of cancers, while its function in bladder cancer
remains unclear. So here we investigated the expression and function of fibulin-1 in Bladder cancer.
Methods: We used real-time PCR, Western blot analysis and immunohistochemistry to determine the expression of
fibulin-1 in Bladder cancer cells and patient tissues respectively. Methylation-specific PCR and quantitative sequencing
were used to examine the methylation status of FBLN1 gene promoter. Eukaryotic expression plasmid and lentiviral
vector were used to overexpress fibulin-1 in Bladder cancer cells 5637, HT-1376 to investigate its function in vitro
and in vivo.
Results: We identified that fibulin-1 was significantly down-regulated in bladder cancer, and its dysregulation was
associated with non-muscle-invasive bladder cancer (NMIBC) grade and recurrence. The promoter region of FBLN1
was generally methylated in bladder cancer cell lines and tissues, further investigation in patient tissues showed that
the methylation status was associated with the fibulin-1 expression. Overexpression of fibulin-1 significantly suppressed
tumor growth, induced tumor cell apoptosis, decreased cell motility, and inhibited angiogenesis in cultured bladder
cancer cells and xenograft tumor in nude mice.
Conclusions: Altogether, our results indicated that fibulin-1 expression is associated with NMIBC grade and recurrence,
it is epigenetically down-regulated and functions as a tumor suppressor gene and angiogenesis inhibitor in bladder
cancer.
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Bladder cancer is the fifth most common malignant disease
in the Western world [1]. Just in US, 70,530 new patients
and 14,680 deaths recorded in 2010 [2]. Approximately
75% of patients with BC present with a disease that is con-
fined to the mucosa (stage Ta, CIS) or submucosa (stage
T1). These categories are grouped as non-muscle-invasive
bladder tumors. Non-muscle invasive BC (NMIBC) has a
high prevalence due to low progression rates and long-term
survival in many cases while it represents a heterogeneous
group of tumors with different rates of recurrence, pro-
gression, and disease-related mortality [3]. In an effort to* Correspondence: xuhua@mail.hust.edu.cn
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unless otherwise stated.improve current diagnosis and management of bladder
cancer, intense researches on identifying clinically helpful
tumor markers or potentially valuable therapeutic targets
have been carried out worldwide [4].
Despite the environment factors such as smoking and
occupational exposures, it is now widely accepted that
genetic and epigenetic alterations of genome are associ-
ated with bladder cancer risk. Genome-wide association
studies of bladder cancer identified single-nucleotide
polymorphisms (SNPs) on chromosome 8q24, upstream
of the MYC oncogene, on chromosome 3q28 near the
TP63 tumor suppressor gene [5], and in the PSCA gene
to be associated with bladder cancer risk [6]. DNA
methylation is one of the most consistent epigenetic
changes occurring in human cancers [7,8]. And it is well
established that aberrant hypermethylation of the promoterd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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transcriptional silencing, and that hypermethylation is
an alternative mechanism of functional inactivation [9]
Moreover, promoter hypermethylation of tumor-related
gene has also been proposed as a novel biomarker for
detecting cancer and predicting prognosis [10].
Recent evidence increasingly points to the important
role of stromal extracellular matrix (ECM) components in
tumor progression; many of ECM proteins interact dir-
ectly with tumor cells, via integrins and other cell-surface
receptors, to influence functions such as proliferation,
apoptosis, migration and differentiation [11]. Fibulin-1
belongs to a growing family of extracellular glycoprotein.
Functionally, fibulin-1 binds to many extracellular matrix
(ECM) proteins, including laminin, fibrinogen, fibronectin,
nidogen-1, and endostatin, and to the proteoglycans,
aggrecan and versican [12,13]. Mice lacking fibulin-1
die perinatally and display vascular anomalies in the
kidney in addition to extensive hemorrhage in several
organs, likely related to abnormalities in endothelial cell
interactions with subendothelial ECM [14]. Fibulin-1 is
reported to involve in the progression of many kinds of
cancers, such as breast, ovarian and prostate cancer
[15-18]. Besides, fibulin-1 has been identified epigenetically
silenced in gastric cancer and hepatocellular carcinoma
through promoter hypermethylation [19,20]. However,
the association between fibulin-1 and bladder cancer
remains unknown. Here we report that fibulin-1 expres-
sion is associated with NMIBC grade and recurrence, it is
epigenetically down-regulated and functions as a tumor
suppressor gene and angiogenesis inhibitor in bladder
cancer.
Methods
Patient and sample collection
The cohort included 139 consecutive patients with NIMBC
treated by TURBT in Chinese People’s Liberation Army
General Hospital from December 2008 to September 2009.
All tumors were initially staged, graded and classified by
pathologists with expertise in genitourinary pathology
according to 2002 TNM classification and 2004 WHO
grading system. Adjuvant therapy of NIMBC after TURBT
included intravesical instillation and chemotherapy. Follow-
up information obtained from medical records of the
patients who fulfilled inclusion criteria included tumor
stage, grade, the development of tumor recurrence, the
presence of multifocal versus unifocal tumor growth,
the co-existence of CIS as well as patient gender and
age. Briefly, patients were seen postoperatively at least
every 3 to 4 months for the first 2 years and semiannually
thereafter. Besides that, telephone follow up was taken
every month. Recurrence was defined as a new tumor
appearing in the bladder after initial clearance. Recurrence
free survival (RFS) was calculated as the time fromTURBT to the date of the first documented bladder tumor
recurrence. The mean follow-up period for the study was
38 months (range, 33–43 months). There was no case
of death in the study. The study protocol was approved
by the Institutional Ethics Committee of Huazhong
University of Science and Technology, Tongji Hospital
and Chinese People’s Liberation Army General Hospital,
and a written informed consent was obtained from all
participants involved in the study.
Cell culture and transfection
Muscle-invasive bladder cancer cell lines 5637, T24, J82
and HT1376 were purchased from ATCC and maintained
in RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS) in a humidified atmosphere of 5%
CO2 maintained at 37°C. SV-HUC-1 was also purchased
from ATCC and maintained in DMEM/F-12 medium.
Primary human umbilical vein endothelial cell (HUVEC)
and Endothelial Cell Medium were purchased from
ALLCELLS, LLC (Shanghai, China). Plasmid transfection
was carried out using FuGene HD Transfection Reagent
(Roche), according to the manufacture’s protocol.
Plasmid, lentivirus and infection
Generally, the full-length coding sequence (CDS) of
FBLN1 was amplified from pBluescript-FBLN1 (Thermo
scientific) and constructed into eukaryotic expression
vector pEGFP-N1 (Clontech) or lentivirus clone vector
pCDH-CMV. Then the lentivirus was packaged and
purified according to the manufacture’s protocol (SBI,
USA). The MOI for 5637 and HT1376 cells was 10 and
5 respectively.
Immunohistochemical (IHC) staining
Besides the specimens of 139 patients in follow-up cohort,
17 normal or adjacent normal bladder tissue specimens
conserved in urology institution, Tongji hospital were also
included in this study. Methods for immunohistochemical
(IHC) staining tissue slides have been described previously
[21]. Depending on the percentage of positive cells and
staining intensity, fibulin-1 staining was classified into
three groups: negative, weak positive and strong positive.
Specifically, the percentage of positive cells was divided
into five grades (percentage scores): <10% (0), 10–25% (1),
25–50% (2), 50–75% (3), and 75% (4). The intensity of
staining was divided into four grades (intensity scores): no
staining (0), light brown (1), brown (2), and dark brown
(3). Fibulin-1 staining positivity was determined by the
formula: overall scores = percentage score × intensity
score. The overall score of ≤3 was defined as negative,
of >3 and ≤6 as weak positive, and of >6 as strong positive.
In some analysis, weak positive and strong positive were
combined as positive to suit the paired statistical analysis.
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Cells were prepared by washing with PBS. Protein
extraction and western blot analysis were performed as
previously described [22]. Primary antibodies included
fibulin-1 (1:500 dilutions; Abcam) and GAPDH (1:1000
dilution; Cell Signaling Technology).
mRNA expression analysis
Total RNA was isolated using RNeasy Mini Kit (Qiagen)
and reverse transcribed using PrimeScript RT Master Mix
(TaKaRa). The resulting cDNA samples were amplified by
real-time PCR using gene-specific primer sets in conjunc-
tion with SYBR Premix Ex Taq (TaKaRa). All the primer
sequences were listed in Additional file 1: Table S1.
DNA methylation analysis by pyrosequencing and
methylation specific PCR
Genomic DNA was isolated using QIAamp DNA Mini Kit
(Qiagen) and bisulfite modification of the genomic DNA
was carried out using an Epitect Bisulfite Kit (Qiagen)
according to the manufacturer’s instructions. Methylation
Specific PCR (MSP) primers were designed with Meth-
primer (http://epidesigner.com). Pyrosequencing for five
CpG sites in the promoter region was performed on a
PyroMark Q96 instrument (Qiagen) according to manufac-
turer’s protocol, as described previously [23]. Record was
analyzed by the manufacturer’s software. All the primer
sequences were listed in Additional file 1: Table S1.
Cell proliferation assay
5637 and HT1376 cells were infected with Lenti-NC or
Lenti-FBLN1 for 48 h. Following treatments, cells were
transferred to 96-well microplates and seeded at a density
of approximately 800 cells per well. Fetal bovine serum
proportion in the culture medium was decreased to 5% to
avoid overgrowth in 72 h. Cell viability was subsequently
determined every 24 h for three days by using the Cell
Counting Kit-8 (CCK-8, Dojindo) according to the
manufacturer’s protocol and Microplate reader (Thermo)
to measure the absorbance.
The effect of fibulin-1 suppression on proliferation
was also tested by the EdU incorporation assay. Briefly,
5637 and HT1376 cells were infected with Lenti-NC or
Lenti-FBLN1 for 48 h. Following treatments, cells were
transferred to 96-well microplates and seeded at a density
of approximately 3 × 103 cells per well for 12 h. Then, cells
were incubated with 50 nM of EdU for an additional 2 h
at 37°C. Cells were fixed with 4% formaldehyde for 15 min
at room temperature and treated with 0.5% Triton X-100
for 20 min at room temperature to permeabilize cells.
After being washed with PBS three times, cells were
incubated with 1× Apollo reaction cocktail (100 μl/well)
for 30 min. DNA was stained with 10 μg/ml of Hoechst
33342 stain (100 μl/well) for 20 min and visualized withfluorescence microscopy. Five groups of confluent cells
were randomly selected from each sample image. EdU-
positive cells were obtained from the fluorescent image,
and the relative positive ratio was calculated from the
average of the five group values.
Colony formation assay
Exponentially growing cells were seeded at approximately
1,000 cells per well in 6-well plates after infection with
Lenti-NC or Lenti-FBLN1. Culture medium was changed
every three days. Colony formation was analyzed ten days
following infection by staining cells with 0.05% crystal
violet solution for 20 min.
Apoptosis analysis
Flow cytometry for cell-apoptosis analysis was performed
as previously described [24]. Briefly, 5637 and HT1376
cells were transfected with pEGFP-N1, pEGFP-FBLN1 or
mock for 72 h. Then cells were collected and stained with
Annexin V-PE and 7-AAD. The early stage apoptosis cells
were detected for Annexin V-PE+/7-AAD−.
In vitro migration and invasion assay
5637 and HT1376 cells were transfected with pEGFP-N1
or pEGFP-FBLN1 for 72 h. About 1 × 105 of 5637 cells or
6 × 104 HT1376 cells were plated in the upper chambers
of 24-well Transwell plates (Corning) in FBS-free medium.
Complete medium (10% FBS) was deposited in the lower
chambers to serve as a chemo-attractant. After 12 h for
5637 or 10 h for HT1376, cells remaining on the upper
filter were removed, while cells that passed through the
Transwell filter were stained by 0.5% crystal violet solution
for 15 min. Images were taken of six random optical fields
(200×) on each filter and cell number was quantified by
utilizing the Image-Pro Plus analysis software (Media
Cybernetics). To evaluate cell invasion, Transwell mem-
branes were coated with Matrigel (BD Biosciences) prior
to plating infected cells. The Matrigel served as a base-
ment membrane barrier that cells would have to destroy
in order to invade the lower chamber. After 22 h for
5637 or 18 h for HT1376, crystal violet staining and cell
counting were performed as above.
In vitro tube formation assay
HUVECs were maintained in basic medium containing
2% FBS and 1% penicillin/ streptomycin or the indicated
conditioned media (CM) of 5637 cells. HUVECs (3 × 104)
were seeded into a 96-well culture plate precoated with
Matrigel (BD Biosciences) overnight and then cultured
in the indicated condition. After 24 h incubation, the
formation of tubes was photographed with a phase contrast
microscopy (10× magnification, Olympus Instruments,
Inc.), and quantified by counting branch points in five
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ments were conducted twice in duplicate.
Animal experiments
Tumorgenesis in nude mice was determined as described
previously [25]. Generally, 5637 bladder cancer cells were
infected with Lenti-NC and Lenti-FBLN1 respectively,
72 h after infection, cells were treated and passaged with
medium containing 2 μg/ml puromycin to establish stable
fibulin-1–expressing cell lines, and then cells were
injected into the right flank of 6-week-old nude mice.
Two groups of five mice each were injected subcutane-
ously with prepared cells at a single site. Tumor onset
measured with calipers at the site of injection weekly
by two trained laboratory staffs at different times on
the same day. Tumor volume was calculated using the
formula, 0.5ab2, where a represent the larger and b rep-
resents the smaller of the two perpendicular indexes.
Animals were sacrificed 28 days after injection. These
tumors were weighed and verified by hematoxylin and
eosin (H&E) staining. The in vivo apoptosis was evaluated
by TUNEL, and the vascularity evaluation was taken by im-
munohistochemical staining with CD31 antibody (Abcam).
The study was conducted after getting approval from
the Institutional Experimental Animal Ethical Committee,
Huazhong University of Science and Technology, China.
Statistical analysis
Statistical significance was determined by using the SPSS
15.0. The Fisher’s exact test was utilized to assess the
significance between different proportions. Analysis of
continuous variables between different groups was as-
sessed by t test. Values are expressed as mean ± SEM
unless otherwise indicated. RFS (recurrence-free survival)
curves were constructed using the Kaplan-Meier method,
and were compared with the log-lank test. The Cox pro-
portional hazards model was used to assess the prognostic
indicators for recurrence. The risk ratio and its 95%
confidence interval were recorded for each marker. All
statistical tests were two-sided, and significance was
defined as p<0.05.
Result
Down-regulation of fibulin-1 expression levels in primary
bladder cancer
Firstly, the expression levels of fibulin-1 in 4 bladder
cancer cell lines (5637, HT1376, J82 and T24) and a
non-tumorigenic bladder cell line SV-HUC-1 were eval-
uated by qPCR and Western blot respectively. Compared
to SV-HUC-1 cells, all of bladder cancer cell lines had a
significantly lower level of fibulin-1 expression in both
mRNA (Figure 1A) and protein levels (Figure 1B).
Fibulin-1 expression was further analyzed by immuno-
histochemistry in a tissue microarray containing 139non-muscle invasive bladder cancer and 17 normal or
adjacent normal bladder tissue specimens (Figure 1C). A
highly significant (Figure 1D, P < 0.01) difference between
the normal and tumor tissues was observed as follows:
23.5% (4 of 17) negative, 29.4% (5 of 17) weak positive and
47.1% (8 of 17) strong positive staining of fibulin-1 in
normal bladder specimens, whereas 54.0% (75 of 139)
negative, 35.2% (49 of 139) weak positive and 10.8% (15
of 139) strong positive staining of fibulin-1 in bladder
cancer samples. Importantly, loss of fibulin-1 expression
was associated with tumor grade (Table 1, P < 0.05), but
not with other clinicopathological parameters such as age,
sex or tumor stage (Table 1, P > 0.05).
Analysis of the association between NMIBC recurrence
and clinicopathological parameters
We then analyzed recurrence-free survival rates to assess
the prognostic significance of the expression of fibulin-1.
The overall recurrence-free survival (RFS) rate of the
139 NMIBC patients was 66.9%. When assessed by
Kaplan–Meier curves, patients with negative fibulin-1
expression tended to have significantly poorer RFS rates
than those in the positive fibulin-1 expression group;
58.7% (negative fibulin-1 expression) and 76.6% (positive
fibulin-1 expression) respectively (Figure 1E, log-rank test,
P = 0.013). When we evaluated whether fibulin-1 negative
expression was independently associated with RFS, several
factors were subsequently investigated in COX regression
analysis. As shown in Table 2, fibulin-1 negative expression
was a significant prognostic factor in COX regression
analysis for RFS (RR: 2.102, 95% CI: 1.130-3.912, P = 0.019).
Promoter methylation analysis of fibulin-1 in bladder cancer
A typical CpG island (CGI) was found around fibulin-1
promoter using the MethPrimer (http://www.urogene.org/
methprimer/index1.html). To explore whether promoter
hypermethylation leads to the suppression of expression,
we examined the expression of FBLN1 in bladder epithe-
lial cell lines treated with the DNA methylation inhibitor,
5-aza-dC. After treatment, all the five cell lines showed a
reactivation of FBLN1 expression (Figure 2A). To further
detect the promoter methylation status of the fibulin-1
qualitatively and quantitatively, the promoter CpG islands
in bladder epithelial cell lines and bladder epithelial tissue
was determined by MSP and quantitative sequencing. As
shown in Figure 2B, MSP results showed hypermethyla-
tion was detected in all bladder cancer cell lines, while
partial methylation in non-tumorigenic cell line SV-
HUC-1, which complied with the 5-aza-dC detection.
For tissues, all two bladder cancer tissues showed
hypermethylation while cancer adjacent tissues showed
partial methylation or unmethylation, which complied
with the mRNA analysis (Figure 2C). To ascertain MSP
reliability, pyrosequencing of the two paired tissues were
Figure 1 Fibulin-1 was down-regulated in bladder cancer. A) Fibulin-1 mRNA and B) protein expression levels were evaluated by qPCR
and Western blot assay respectively in bladder cancer cell lines. GAPDH served as an internal control and loading control. C) Representative
microphotographs of fibulin-1 staining in patient tissues. D) Summary of fibulin-1 expression determined by immunohistochemistry in NMIBC
patient tissue samples. E) Kaplan-Meier estimate of recurrence-free survival stratified by fibulin-1 expression in 139 NMIBC patients.




Negative (75) Weak (49) Strong (15)
Sex 0.909
Men 102 54 (52.9%) 37 (36.3%) 11 (10.8%)
Women 37 21 (56.8%) 12 (32.4%) 4 (10.8%)
Age (years) 0.657
<average(62) 64 32 (50.0%) 24 (37.5%) 8 (12.5%)
≥average(62) 75 43 (57.3%) 25 (33.3%) 7 (9.4%)
Grade <0.01*
Low grade 91 40 (44.0%) 37 (40.7%) 14 (15.4%)
High grade 48 35 (72.9%) 12 (25.0%) 1 (2.1%)
Stage 0.225
PTa 63 36 (57.1%) 18 (28.6%) 9 (14.3%)
PT1 76 39 (51.3%) 31 (40.8%) 6 (7.9%)
*Two-tailed fisher’s exact test was done to determine the relationship of fibulin-1 expression with various variables and statistical significance was set at P < 0.05.
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Table 2 Multivariate Cox regression analysis of potential








Sex 0.548 0.786 0.409 1.510
Age 0.225 0.754 0.419 1.356
Grade 0.000* 6.326 3.318 11.392
Stage 0.512 1.085 0.597 1.974
Fibulin-1 expression 0.019* 2.102 1.130 3.912
*P value was considered to indicate statistical significance.
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results (Figure 2D). Then we systematically analyzed the
MSP and IHC results of the 139 patient tissue samples.
Remarkably, a statistically significant (P < 0.01, two-tailed
χ2 test) inverse correlation between fibulin-1 expression
and methylation was found (Figure 2E). Together, these
results suggested that fibulin-1 was down-regulated
through promoter hypermethylation in bladder cancer.Fibulin-1 suppressed bladder cancer cells proliferation
and tumorigenicity
Current data indicate that FBLN1 might have a tumor
suppressive function. We investigated its tumor suppressive
function by a gain-of-function strategy. We first detected
fibulin-1’s function on cell proliferation by CCK-8 and EdU
assay. After re-expression of FBLN1 in 5637 and HT1376
cells, the number of viable cells significantly reduced com-
pared to the negative control (Figure 3A, P < 0.05). The
EdU detection confirmed that re-expression of fibulin-1
could effectively inhibit cancer cell proliferation (Figure 3B,
P < 0.05). Then, the fibulin-1’s function on tumorigenicity
was detected in vitro. A lentivirus carrying FBLN1 was
used in this study. After infected with Lenti-NC or
Lenti-FBLN1 respectively, a monolayer colony forma-
tion assay was carried out, the results showed that the
colonies formed on the plate were significantly decreased
(Figure 3C, P < 0.01). These results suggested that
fibulin-1 suppressed bladder cancer cells proliferation
and tumorigenicity in vitro.Fibulin-1 induced bladder cancer cells apoptosis
Next, apoptosis in cancer cells were detected. For bladder
cancer cells 5637 and HT1376, we used flow cytome-
try analysis based on Annexin V staining, as shown in
Figure 3D, 72 h post transfection, the average early
apoptosis rates (Annexin V-PE+/7-AAD−) of FBLN1-
transfected 5637 and HT1376 cells were 31.12% and
17.91% respectively, which were significantly higher
when compared to the control vector-transfected cells
(10.04% and 9.64%, P < 0.05).Fibulin-1 suppressed bladder cancer cells motility and
angiogenesis
As a novel ECM protein, we hypothesized that fibulin-1
may also play a role in bladder cell motility. To test this
hypothesis, 5637 and HT1376 bladder cancer cells, which
contain promoter methylation and lack fibulin-1 expres-
sion, were transfected to overexpress fibulin-1. Analysis of
cell migration and invasion by Transwell assays revealed
that fibulin-1 expression significantly suppressed migra-
tion and invasion of 5637 (Figure 4A and B) and HT1376
(Figure 4C and D) cell lines (P < 0.05).
To characterize the in vitro effects of fibulin-1 on
angiogenesis, an endothelial tube assay was performed.
Tube formation by activated HUVECs was achieved by
the conditioned media (CM) of 5637 cells or CM of 5637
cells transfected with pEGFP-N1 vehicle. The angiogenic
activity of CM lost by ectopic overexpression of fibulin-1,
while it was restored by pretreated with antibody against
fibulin-1 (Figure 4E and F). The results of this assay
demonstrated that fibulin-1 inhibited angiogenesis in vitro.In vivo tumor study with fibulin-1
We assessed FBLN1 tumor suppressor activity also in vivo.
As shown in Figure 5A and B, the latency of tumor growth
in mice with fibulin-1 expressing 5637 cancer line was
significantly longer when compared to the control, and the
average tumor volume in mice with fibulin-1 expressing
group were significantly smaller than the control group.
The mice were sacrificed 28 days after tumor cell
injections and tumors in each group were harvested and
sectioned. Apoptosis in tumor samples was detected by
TUNEL assay. Fibulin-1 induced apoptosis much more
robustly when compared to the control (Figure 5C and D,
P < 0.05). To further characterize the in vivo effects of
fibulin-1 on angiogenesis, 5637 tumors were evaluated for
blood vessel density. The tumors were labeled with CD31,
an endothelial cell–specific marker. Immunohistochemistry
results revealed that blood vessel quantification reduced
drastically in the 5637 tumors over-expressing fibulin-1
(Figure 5C and E, P < 0.05), which indicated that fibulin-1
significantly inhibit bladder tumor angiogenesis.Discussion
Fibulin-1 is an extracellular matrix and plasma protein that
has been implicated as playing a role in tumor progression
[16,20,26-29]. Our data revealed the expression of fibulin-1
was significantly decreased or lost in bladder cancer tissues
and cell lines. Using IHC analysis of 139 non-muscle inva-
sive bladder cancer patient tissue samples, we found the
expression of fibulin-1 in NMIBC was associated with
tumor grade, indicated that loss of fibulin-1 expression may
contribute to bladder cancer progression, these results
accord with our previously observations of fibulin-5 in
Figure 2 Fibulin-1 was silenced in bladder cancer by promoter hypermethylation. A) fibulin-1 expression in five bladder cell lines with or
without 5-aza-dC treatment was determined by real-time RT-PCR. The results are the average of three independent experiments normalized to
GAPDH levels. B) fibulin-1 methylation status in 5 bladder cell lines and two matched pairs of normal (N)/tumor (T) bladder tissues were analyzed
by MSP. (M) amplification using primers specific for methylated DNA. (U) amplification using primers specific for unmethylated DNA. IVD (in vitro
methylated DNA) and ddH2O were positive and negative controls, respectively. C) qPCR was used to analyze fibulin-1 expression in two matched pairs
of bladder tissues mentioned in B). D) Pyrosequencing of fibulin-1 promoter region two matched pairs of bladder tissues mentioned in B), the average
methylation rate of 5 CpG was listed. E) The correlation analysis of fibulin-1 expression and methylation in 139 NMIBC patient samples.
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of fibulin-1 in cancer cell lines was a little different with
tissue samples. 5637 cells, which derived from a grade 2bladder transitional cell carcinoma had the lower fibulin-1
expression than J82 or T24 cells which originated from
high grade, invasive human bladder cancer. Implying that
Figure 3 Fibulin-1 functioned as a tumor suppressor in bladder cancer cells. The effect of ectopic FBLN1 expression on tumor cell
proliferation was investigated by A) CCK-8 and B) EdU assay in 5637 and HT1376 cells. Data are plotted as the mean ± SD of 3 independent
experiments relative to mock treatments. C) The effect of ectopic FBLN1 expression on tumor cell tumorgenesis was investigated by the
monolayer colony-formation assay. Quantitative analyses of colony numbers are shown as mean ± SD. D) Fibulin-1 induced apoptosis of bladder
cancer cells. The early stage apoptosis cells were detected for Annexin V-PE+/7-AAD-. Quantitative analyses of apoptotic cell numbers are shown in
the right panel as values of mean ± SD. Asterisk indicates p < 0.05.
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cancer tissues might be different.
Epigenetic alterations such as promoter hypermethyla-
tion can lead to the transcriptional silencing of tumor
suppress genes, which is important for preventing cancerdevelopment. Fibulin-1 has been found epigenetically
silenced in gastric cancer and hepatocellular carcinoma
through promoter hypermethylation [19,20]. Using methyl-
ation-specific PCR and quantitative sequencing, we found
the promoter regions of fibulin-1 were generally methylated
Figure 4 Fibulin-1 inhibited motility and angiogenesis activation of bladder cancer cells. A) 5637 and C) HT1376 cells were transfected
with pEGFP-N1 or pEGFP-FBLN1 for 72 h and then the abilities of cell migration and invasion were detected respectively. Representative images
showed results of one assay, B) and D) the column chart showed the mean ± SD of five randomly selected microscope fields per well. E) Tube
formation of HUVECs was determined by assaying the numbers of branch nodes after 24 h of culture under a phase contrast microscope. HUVECs
were cultured in the following media: conditioned media (CM) of 5637 cells, CM of 5637 cells transfected with pEGFP-N1, CM of 5637 cells transfected
with pEGFP-FBLN1 and CM of 5637 cells transfected with pEGFP-FBLN1 with fibulin-1 antibody pretreatment. F) The summary and statically analysis of
E). All these experiments were repeated at least three times. Asterisk indicates p < 0.05.
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and tissues. Remarkably, we found the transcription level
of fibulin-1 in bladder cancer cells increased as expected
after 5-AZA-dC treatment, but it was still well below that
in bladder non-tumorgenetic cell line SV-HUC-1. This
observation indicated that there might be some other
mechanisms that regulated fibulin-1 expression. For
example, fibulin-1 maturation and mislocalisation have
been found in breast cancer [27], while in prostate cancer,
fibulin-1 was also down-regulated but did not induce by
5-aza-2′-deoxycytidine [31].
Many studies have investigated molecular biomarkers
for prediction of risk and recurrence of bladder cancer.
To date, several molecular markers have been reported to
be associated with bladder cancer recurrence [32-34]. Our
results now identified fibulin-1 expression as associatedwith the recurrence-free survival of non-muscle invasive
bladder cancer patients. Although the sample size in our
study was relatively small and needed further ascertain, to
our knowledge, this is the first study to provide evidence
that fibulin-1 expression may play an important role in
the prediction of NMIBC recurrence.
In the latter part of the study, we systematically inves-
tigated the tumor suppressing function of fibulin-1 in
bladder cancer cells. As a novel ECM protein, fibulin-1 had
been reported a multifunction protein in variable aspects
of tumor cells, such as cell motility [35], cell proliferation
[20], apoptosis and angiogenesis [36]. Our findings from
in vitro and in vivo experiments proved that overexpress-
ing fibulin-1 suppressed tumor growth, induced tumor
cell apoptosis, decreased cell motility, and inhibited angio-
genesis in bladder cancer cells. These tumor suppressing
Figure 5 Fibulin-1 suppressed bladder cancer in vivo. Five mice were used per group conducted by 5637 cells transduced to express blank
vehicle (Lenti-NC) or fibulin-1 (Lenti-FBLN1). A) Tumor growth curves of xenograft inoculated in nude mice. Curves represent average tumor size
of 5 mice per time point. B) Representative images showed the xenograft tumors. C) Representative tumor sections of xenograft tumors derived
from 5637 cells transduced to express Lenti-NC (a–c) and Lenti-FBLN1 (d–f). (a) and (d) show H&E stained images; (b) and (e), TUNEL of the xeno-
graft tumors, white arrows showed the positive plots; (c) and (f), immunohistochemistry for CD31 (in dark brown color). D) Quantitative analyses
of TUNEL are shown as mean ± SD of five randomly selected microscope fields per slice of mice in the two groups. E) The mean ± SD of blood
vessel number of five randomly selected microscope fields per slice of mice in the two groups. Asterisk indicates p < 0.05.
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http://www.biomedcentral.com/1471-2407/14/677functions of FBLN1 corresponded with its loss of
expression in bladder cancers. We conjectured that the
methylation degree of FBLN1 promoter increased in
the progression progress of bladder cancer, which resulted
in the loss of fibulin-1 expression, so that enhanced
the bladder tumor growth and ability of metastasis and
angiogenesis.
Conclusions
In conclusion, our study provides evidences that FBLN-1
functions as a novel candidate tumor-suppressor gene in
bladder cancers and its down-regulation maybe due to
the promoter hypermethylation. Restoration of fibulin-1expression significantly inhibited bladder cancer cell
growth, motility and angiogenesis, which are indicative
features of tumor suppressor gene. The dysregulation
of fibulin-1 is associated with NMIBC grade and
recurrence. Further studies are needed to determine
the potential usefulness of assessing FBLN1 in bladder
cancer as a prognostic marker and candidate target for
gene therapy.Additional file
Additional file 1: Table S1. Primer sets sequences used in this study.
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